RankAlpha logo

AUNA

AI Memo

Auna

As of 2026-11-07/Confidence low
Data freshness
AI Memo
As of 2026-11-07 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action
—
Confidence
low
Horizon
—
Key catalyst
Third-quarter results and Colombia contract review • 2026-11-17
Base target: $5 / p=45% prob
Biggest risk
The Colombia payor-contract cost pressure has already displaced expected 2026 adjusted EBITDA growth with broadly flat year-over-year performance. The magnitude and duration remain under company review. [#IR-2026-10-22] Company outlook
Invalidation
Break below $3 or thesis failure.
What would change my mind?
Higher preliminary surgery volumes across all three countries and Auna's expectation that revenue growth remains in line with prior guidance could support recovery if Colombia contract costs prove temporary. [#PR-EARNINGS-2026-10-15] [#IR-2026-10-22] Company outlook
Research note
Recommendation
—
Confidence
low
As of
2026-11-07
Base target
$5
p=45%
Bull target
$6
p=25%
Bear target
$3
p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets
  • Surgery-volume gains versus oncology costs
  • Centro Ambulatorio Trecca construction
  • Higher preliminary surgery volumes across all three countries and Auna's expectation that revenue growth remains in line with prior guidance could support recovery if Colombia contract costs prove temporary.
BearKey bullets
  • Auna has not yet completed its review of the contract's full-year adjusted EBITDA implications.
  • [#IR-2026-10-22] Company outlook
  • Trecca's projected late-2028 opening depends on construction execution and milestone payments.
WatchKey bullets
  • Third-quarter results and Colombia contract review

Summary

High-level snapshot

Recommendation
-
Model confidence
low
Timeframe
-
Asset
Equity
Trigger
-
Base case: $5 (p=45%)
Target spread vs base: +30% / -26%
Scenario probabilities
Bull Target: $6 (p=25%)Base Target: $5 (p=45%)Bear Target: $3 (p=30%)
Commentary
The October 22 EBITDA outlook reduction dominates the available news despite favorable preliminary volume indicators. A measured announcement-day price reaction and post-guidance analyst revisions were not verified. Social, options, short-interest and employee measures are unavailable; zeroes in those fields mean missing data, not neutral readings. Low coverage and weak direct-peer comparability limit conviction.
As of 2026-11-07 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case
Higher preliminary surgery volumes across all three countries and Auna's expectation that revenue growth remains in line with prior guidance could support recovery if Colombia contract costs prove temporary. [#PR-EARNINGS-2026-10-15] [#IR-2026-10-22] Company outlook
Bear Case
The Colombia payor-contract cost pressure has already displaced expected 2026 adjusted EBITDA growth with broadly flat year-over-year performance. The magnitude and duration remain under company review. [#IR-2026-10-22] Company outlook

Drivers

Scannable catalysts and supporting factors

  • Surgery-volume gains versus oncology costs
  • Centro Ambulatorio Trecca construction

Scenarios

Bull Target (Scenario probability)
$6 / p=25% prob
Base Target (Scenario probability)
$5 / p=45% prob
Bear Target (Scenario probability)
$3 / p=30% prob
Analysis 2026-11-07 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)
-0.40
Social Sentiment (7d)
0.00

Events

Other notable items detected

  • EVENT2026-11-17
    Third-quarter results and Colombia contract review
    Auna scheduled its release for November 17 and call for November 18. The key test is whether it quantifies the duration and cost of the Colombia payor-contract pressure behind its reduction of expected 2026 adjusted EBITDA growth from the low end of 10%–14% FX-neutral to broadly flat year over year. [#IR-2026-10-13] Reporting dates [#IR-2026-10-22] Company outlook
    Prob 95.00% • Move -8.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

  • Surgery-volume gains versus oncology costs
    2026-12-31
    Preliminary third-quarter surgery counts rose year over year in Mexico, Peru and Colombia, but Auna attributed its reduced EBITDA outlook to unexpected advanced-stage cancer costs under a Colombia payor contract. Whether volume growth offsets that pressure remains unproven. [#PR-EARNINGS-2026-10-15] [#IR-2026-10-22] Company outlook
    Prob 55% • Move -5% • Priced-in 50%

Long-term Catalysts

Months to a year

  • Centro Ambulatorio Trecca construction
    2028-12-31
    Auna says the conditions precedent to construction of its Peru public-private partnership have been fulfilled and projects operations in late 2028. Construction milestones and eventual returns remain execution questions, not near-term earnings support. [#IR-2026-10-21] Company announcement
    Prob 60% • Move 8% • Priced-in 20%

Risks

  • Auna has not yet completed its review of the contract's full-year adjusted EBITDA implications. [#IR-2026-10-22] Company outlook
  • Trecca's projected late-2028 opening depends on construction execution and milestone payments. [#IR-2026-10-21] Company announcement
  • Unexpected advanced-stage cancer costs under a Colombia payor contract may persist or spread beyond current assumptions. [#IR-2026-10-22] Company outlook

Peers

SymbolSummary
ABTBroad healthcare-sector reference only. Its device and diagnostics businesses and much larger scale make it unsuitable as a direct valuation peer for Auna's Latin American healthcare-services and plan platform.
EMBCSimilar supplied market-cap range, but a medical-device business rather than a hospital and health-plan operator; not a direct valuation peer.

Sources

Internal and external references used in this analysis

  • Model source: RankAlpha Sentiment Codex
  • Analysis date: 2026-11-07